Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives, Inc. develops and markets nutraceutical and wellness products for cognitive performance, brain recovery, pet vitality and weight management. Company news centers on the MyndSystem platform, including MyndMed for daytime cognitive support and MyndRenew for nighttime recovery support, as well as NeuroRush, PawPa Regen dog chews and Zeranovia.
Recurring updates cover product launches, direct-to-consumer availability, formulation positioning, pilot and dosage testing, athlete-safety testing for MyndMed, and expansion of pet-wellness and nootropic product lines.
BioAdaptives (OTC: BDPT) launched MyndSystem™, a stimulant-free, dual-phase cognitive support platform combining daytime and nighttime formulas for a 24-hour brain support cycle.
MyndMed™ targets daytime performance, while MyndRenew™ focuses on overnight repair. A 30-day system costs $159.90 one-time or $119.93 by subscription at myndsystem.com.
BioAdaptives (OTC: BDPT) launched MyndRenew on May 6, 2026, a nighttime dietary supplement aimed at supporting sleep quality and the brain's overnight recovery processes as part of the MyndSystem platform.
MyndRenew contains 13 ingredients at research-consistent levels, including magnesium glycinate, apigenin, PEA, and lion's mane extract, and is available now at www.myndsystem.com.
BioAdaptives (OTC: BDPT) launched MyndSystem™, a two-product neuro-performance and repair system for day and night, on April 28, 2026. MyndMed™ (day) targets focus, clarity, endurance, and stress resilience; MyndRenew™ (night) targets Delta-wave sleep, glymphatic waste removal, and mitochondrial repair. The company published a clinical evidence library and launched a direct-to-consumer website at www.MyndSystem.com. BioAdaptives will share updates via X at @BioAdaptivesInc.
BioAdaptives (OTC: BDPT) announced the commercial launch of MyndMed™, a cognitive-support dietary supplement available online as of October 7, 2025.
The company said MyndMed™ combines well-studied nutrients targeting cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity, and that manufacturing occurs in cGMP-certified U.S. facilities with third‑party testing and transparent labeling. BioAdaptives is scaling production to meet expected high order volumes beginning in November and offers nationwide U.S. shipping, introductory promotions, and subscription options at www.MyndMed.com.
BioAdaptives (OTCMKTS: BDPTD) announced that its nootropic supplement MyndMed™ has received full clearance from TruShield™ Laboratory Services, confirming compliance with World Anti-Doping Agency (WADA) and Ultimate Fighting Championship (UFC) standards.
The comprehensive testing verified that MyndMed™, which combines botanical extracts, amino acids, and neuro-support nutrients, contains no banned or prohibited substances. This certification enables UFC athletes to use the supplement without concerns about anti-doping violations.
The product is designed to enhance focus, reaction time, and cognitive performance while supporting neurotransmitter balance and neural resilience for athletes under high-stress competition conditions.
BioAdaptives (OTC:BDPTD) announced the national launch of NeuroRush™, a next-generation nootropic supplement, scheduled for commercial release in August/September 2025. The product combines six clinically studied ingredients including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens.
The supplement will be available in two formulations: one with natural caffeine and a caffeine-free version. Following successful test market results, the company plans to distribute NeuroRush™ through online retailers, direct-to-consumer channels, and health & wellness partners nationwide.
BioAdaptives (OTC Pink: BDPTD) announced the nationwide launch of Pawpa™ Regen, a revolutionary canine supplement designed to promote regenerative healing through stem cell activation in aging dogs. Following a successful limited market release, the product will be available nationwide through e-commerce platforms by late July 2025.
The proprietary formula works by stimulating the release of circulating stem cells, leading to improvements in vitality, mobility, and overall wellness in older dogs. Early testing has shown positive results in energy levels, coat health, mobility, and temperament. The company is scaling production to meet anticipated strong demand in the pet wellness market.
BioAdaptives Inc. (OTC: BDPT) has announced successful completion of dosage trials for its weight loss product Zeranovia™. The trial demonstrated significant results, with participants experiencing weight loss of 5-7 pounds per week with minimal side effects.
Key findings include consistent weight loss across participants, with the main side effect being mild gastrointestinal discomfort, manageable through increased water intake or dosage adjustments. All trial subjects requested to proceed to the next phase, demonstrating high satisfaction levels.
Based on these promising results, BioAdaptives is proceeding with dosage adjustments for the next stage of clinical trials, aiming to address the global need for effective and safe weight loss solutions.
BioAdaptives Inc. (OTC: BDPT) has appointed Reed Harris to its Board of Advisors. Harris, currently serving as Senior Vice President of Athlete Development and Marketing at UFC, brings over 40 years of experience in leadership and business management. He is the founder of World Extreme Cagefighting (WEC), which he sold to UFC in 2006 and managed until its 2012 merger.
Harris will collaborate with BioAdaptives' marketing department to launch several new products, including Xcellera, a stem cell activator. Clinical trials have shown Xcellera increases circulating stem cells by 268.8% in 28 days, supporting tissue repair, anti-aging, immune and cardiovascular functions.